---
figid: PMC7600801__cancers-12-02801-g001
figtitle: 'MAPK signaling pathway (A) in a BRAF inhibitor-sensitive cell showing sites
  of action of BRAF inhibitors and MEK inhibitors, and (B) after BRAF inhibitor resistance
  development '
organisms:
- NA
pmcid: PMC7600801
filename: cancers-12-02801-g001.jpg
figlink: pmc/articles/PMC7600801/figure/cancers-12-02801-f001/
number: F1
caption: 'The MAPK signaling pathway (A) in a BRAF inhibitor-sensitive cell showing
  sites of action of BRAF inhibitors and MEK inhibitors, and (B) after BRAF inhibitor
  resistance development []. Mechanisms of resistance are numbered: (1) upregulation
  of RTK; (2) BRAF amplification; (3) BRAF alternative splicing; (4) loss of NF1;
  (6) ERK activation; (7) loss of PTEN; and (8) activation of alternative signaling
  pathways. BRAF, v-Raf murine sarcoma viral oncogene homolog B; ERK, extracellular
  signal-regulated kinase; GFR, growth factor receptor; mTOR, mammalian target of
  rapamycin; NF1, neurofibromin 1; PTEN, phosphatase and tensin homolog; RTK, receptor
  tyrosine kinase. From Tanda et al. Frontiers in Molecular Biosciences 2020, 7, 154
  []. © 2020 Tanda, Vanni, Boutros, Andreotti, Bruno, Ghiorzo and Spagnolo.'
papertitle: 'Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic
  Review.'
reftext: Ilaria Proietti, et al. Cancers (Basel). 2020 Oct;12(10):2801.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8982118
figid_alias: PMC7600801__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC7600801__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7600801__cancers-12-02801-g001.html
  '@type': Dataset
  description: 'The MAPK signaling pathway (A) in a BRAF inhibitor-sensitive cell
    showing sites of action of BRAF inhibitors and MEK inhibitors, and (B) after BRAF
    inhibitor resistance development []. Mechanisms of resistance are numbered: (1)
    upregulation of RTK; (2) BRAF amplification; (3) BRAF alternative splicing; (4)
    loss of NF1; (6) ERK activation; (7) loss of PTEN; and (8) activation of alternative
    signaling pathways. BRAF, v-Raf murine sarcoma viral oncogene homolog B; ERK,
    extracellular signal-regulated kinase; GFR, growth factor receptor; mTOR, mammalian
    target of rapamycin; NF1, neurofibromin 1; PTEN, phosphatase and tensin homolog;
    RTK, receptor tyrosine kinase. From Tanda et al. Frontiers in Molecular Biosciences
    2020, 7, 154 []. © 2020 Tanda, Vanni, Boutros, Andreotti, Bruno, Ghiorzo and Spagnolo.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RAPGEF5
  - KRAS
  - HRAS
  - NRAS
  - RAF1
  - BRAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - NF1
  - PTEN
  - MTOR
  - NFKB1
  - MDM2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - TP53
  - MAP3K8
  - CROT
  - gfr
  - nac
  - Tie
  - Ras85D
  - InR
  - ras
  - Ras64B
  - Dsor1
  - Mtk
  - Erk7
  - rl
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Nf1
  - Pten
  - Mtor
  - Tor
  - Dif
  - dl
  - Rel
  - Stat92E
  - mir-ban
  - Vemurafenib
  - Dabrafenib
  - Encorafenib
  - Cobimetinib
  - Trametinib
  - Binimetinib
---
